What is Samsung Biologics?
Samsung Biologics is a biologics contract development and manufacturing company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Biologics contract development and manufacturing
- Headquarters
- Incheon, South Korea
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; KRX: 207940
What is Samsung Biologics?
Samsung Biologics is a biologics contract development and manufacturing company headquartered in Incheon, South Korea. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Samsung Biologics is a biologics contract development and manufacturing company headquartered in Incheon, South Korea. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Samsung Biologics should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Samsung Biologics offer?
Samsung Biologics's profile centers on Biologics manufacturing, CDMO services, Cell culture, Drug substance.
- Biologics manufacturing· Biologics contract development and manufacturing
- CDMO services· Biologics contract development and manufacturing
- Cell culture· Biologics contract development and manufacturing
- Drug substance· Biologics contract development and manufacturing
- Fill-finish· Biologics contract development and manufacturing
- Quality systems· Biologics contract development and manufacturing
How does Samsung Biologics make money?
Samsung Biologics makes money through commercial activity tied to biologics contract development and manufacturing.
Samsung Biologics monetizes through the model common to biologics contract development and manufacturing: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Samsung Biologics?
Samsung Biologics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Samsung Biologics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Samsung Biologics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Samsung Biologics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Samsung Biologics's leadership?
Samsung Biologics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://samsungbiologics.com- Samsung Biologics investor relationsInvestor relations / corporate contactcontact via https://samsungbiologics.com
- Samsung Biologics sales or partnershipsCommercial contact routecontact via https://samsungbiologics.com
- Samsung Biologics media relationsMedia or communications contact routecontact via https://samsungbiologics.com
How is Samsung Biologics funded?
Samsung Biologics's current status is Public company; KRX: 207940.
Samsung Biologics's capital profile is best understood through its current public-company status: Public company; KRX: 207940. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Samsung Biologics get here?
Samsung Biologics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingSamsung Biologics is foundedThe company begins building in biologics contract development and manufacturing.
- Scale-upCommercial footprint expandsSamsung Biologics broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; KRX: 207940Public-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Samsung Biologics's competitors?
Samsung Biologics competes with larger incumbents and focused specialists in biologics contract development and manufacturing.
Samsung Biologics — frequently asked questions
